{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T18:39:57Z","timestamp":1706380797003},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10552-018-1106-0","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T03:19:24Z","timestamp":1543547964000},"page":"97-101","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Rinat","family":"Bernstein-Molho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Laitman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagit","family":"Schayek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Iomdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/bcr3405","volume":"15","author":"AK Win","year":"2013","unstructured":"Win AK, Lindor NM, Jenkins MA (2013) Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res BCR 15:R27","journal-title":"Breast Cancer Res BCR"},{"key":"1106_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.254","author":"ME Roberts","year":"2018","unstructured":"Roberts ME, Jackson SA, Susswein LR, Zeinomar N, Ma X, Marshall ML et al (2018) MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet Med. \n                    https:\/\/doi.org\/10.1038\/gim.2017.254","journal-title":"Genet Med"},{"issue":"11","key":"1106_CR3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/bjc.2017.348","volume":"117","author":"C Therkildsen","year":"2017","unstructured":"Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M (2017) Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer 117(11):1702\u20131710","journal-title":"Br J Cancer"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","volume":"30","author":"C Engel","year":"2012","unstructured":"Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W et al (2012) Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol 30:4409\u20134415","journal-title":"J Clin Oncol"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2016.71.9260","volume":"35","author":"CR Espenschied","year":"2017","unstructured":"Espenschied CR, LaDuca H, Li S, McFarland R, Gau C-L, Hampel H (2017) Multigene panel testing provides a new perspective on Lynch syndrome. J Clin Oncol 35:2568\u20132575","journal-title":"J Clin Oncol"},{"key":"1106_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/gte.1997.1.47","volume":"1","author":"M Robson","year":"1997","unstructured":"Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T et al (1997) Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47\u201351","journal-title":"Genet Test"},{"key":"1106_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185\u2013187","journal-title":"Nat Genet"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1086\/301903","volume":"63","author":"FH Fodor","year":"1998","unstructured":"Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI et al (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45\u201351","journal-title":"Am J Hum Genet"},{"key":"1106_CR9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnci\/91.14.1241","volume":"91","author":"E Warner","year":"1999","unstructured":"Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241\u20131247","journal-title":"J Natl Cancer Inst"},{"key":"1106_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1006\/gyno.2000.5848","volume":"78","author":"DH Tobias","year":"2000","unstructured":"Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR et al (2000) Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol 78:148\u2013151","journal-title":"Gynecol Oncol"},{"key":"1106_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1399-0004.2010.01594.x","volume":"79","author":"L Raskin","year":"2011","unstructured":"Raskin L, Schwenter F, Freytsis M, Tischkowitz M, Wong N, Chong G et al (2011) Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. Clin Genet 79:512\u2013522","journal-title":"Clin Genet"},{"key":"1106_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1053\/j.gastro.2011.02.071","volume":"140","author":"B Mukherjee","year":"2011","unstructured":"Mukherjee B, Rennert G, Ahn J, Dishon S, Lejbkowicz F, Rennert HS et al (2011) High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. Gastroenterology 140:1919\u20131926","journal-title":"Gastroenterology"},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/345075","volume":"71","author":"WD Foulkes","year":"2002","unstructured":"Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C et al (2002) The founder mutation MSH2*1906G\u2192C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 71:1395\u20131412","journal-title":"Am J Hum Genet"},{"key":"1106_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10689-011-9507-1","volume":"11","author":"Y Laitman","year":"2012","unstructured":"Laitman Y, Herskovitz L, Golan T, Kaufman B, Paluch SS, Friedman E (2012) The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. Fam Cancer 11:243\u2013247","journal-title":"Fam Cancer"},{"key":"1106_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ygyno.2010.08.027","volume":"119","author":"F Barak","year":"2010","unstructured":"Barak F, Milgrom R, Laitman Y, Gemer O, Rabinovich A, Piura B et al (2010) The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecol Oncol 119:511\u2013515","journal-title":"Gynecol Oncol"},{"key":"1106_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cancergen.2015.11.003","volume":"209","author":"H Schayek","year":"2016","unstructured":"Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L et al (2016) The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet 209:50\u201352","journal-title":"Cancer Genet"},{"key":"1106_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3878","volume":"15","author":"HT Lynch","year":"2015","unstructured":"Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP (2015) Milestones of Lynch syndrome: 1895\u20132015. Nat Rev Cancer 15:181\u2013194","journal-title":"Nat Rev Cancer"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25\u201333","journal-title":"Cancer"},{"key":"1106_CR19","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/npjgenmed.2015.3","volume":"1","author":"ESY Wong","year":"2016","unstructured":"Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS et al (2016) Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. NPJ Genom Med 1:15003","journal-title":"NPJ Genom Med"},{"key":"1106_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jamaoncol.2017.1996","volume":"3","author":"T Walsh","year":"2017","unstructured":"Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK et al (2017) Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol 3:1647\u20131653","journal-title":"JAMA Oncol"},{"key":"1106_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10689-009-9298-9","volume":"9","author":"Y Goldberg","year":"2010","unstructured":"Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T et al (2010) An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC. Fam Cancer 9:141\u2013150","journal-title":"Fam Cancer"},{"key":"1106_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jmau.2016.10.002","volume":"5","author":"TA Shah","year":"2017","unstructured":"Shah TA, Guraya SS (2017) Breast cancer screening programs: review of merits, demerits, and recent recommendations practiced across the world. J Microsc Ultrastruct 5:59\u201369","journal-title":"J Microsc Ultrastruct"},{"key":"1106_CR23","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1158\/1538-7445.AM2017-4755","volume":"77","author":"H Davies","year":"2017","unstructured":"Davies H, Morganella S, Purdie CA, Jang SJ, Borgen E, Russnes H et al (2017) Whole-genome sequencing reveals breast cancers with mismatch repair deficiency. Cancer Res 77:4755","journal-title":"Cancer Res"},{"key":"1106_CR24","unstructured":"Research C for DE and Approved Drugs\u2014FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. \n                    https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm560040.htm\n                    \n                  . Accessed 22 May 2018"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-018-1106-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-018-1106-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-018-1106-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,30]],"date-time":"2019-11-30T00:03:56Z","timestamp":1575072236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-018-1106-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s10552-018-1106-0","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"12 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}